WO2000069897A3 - Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes - Google Patents

Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes Download PDF

Info

Publication number
WO2000069897A3
WO2000069897A3 PCT/US2000/013166 US0013166W WO0069897A3 WO 2000069897 A3 WO2000069897 A3 WO 2000069897A3 US 0013166 W US0013166 W US 0013166W WO 0069897 A3 WO0069897 A3 WO 0069897A3
Authority
WO
WIPO (PCT)
Prior art keywords
pdz
cd3n
dhr
lymphocytes
modulation
Prior art date
Application number
PCT/US2000/013166
Other languages
French (fr)
Other versions
WO2000069897A2 (en
WO2000069897A9 (en
Inventor
Pater S Lu
Original Assignee
Arbor Vita Corp
Pater S Lu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbor Vita Corp, Pater S Lu filed Critical Arbor Vita Corp
Priority to AU50114/00A priority Critical patent/AU5011400A/en
Publication of WO2000069897A2 publication Critical patent/WO2000069897A2/en
Publication of WO2000069897A3 publication Critical patent/WO2000069897A3/en
Publication of WO2000069897A9 publication Critical patent/WO2000069897A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in hematopoietic cells and other cells involved in the mediation of an immune response. Reagents and methods provided are useful for treatment of a variety of diseases and conditions mediated by immune system cells. Reagents inhibit or enhance the binding of a PDZ motif containing protein and a PL protein (CD3eta).
PCT/US2000/013166 1999-05-14 2000-05-12 Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes WO2000069897A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50114/00A AU5011400A (en) 1999-05-14 2000-05-12 Molecular interactions in t cells

Applications Claiming Priority (26)

Application Number Priority Date Filing Date Title
US13411799P 1999-05-14 1999-05-14
US13411899P 1999-05-14 1999-05-14
US13411499P 1999-05-14 1999-05-14
US16086099P 1999-10-21 1999-10-21
US16249899P 1999-10-29 1999-10-29
US17045399P 1999-12-13 1999-12-13
US60/170,453 1999-12-13
US17619500P 2000-01-14 2000-01-14
US60/176,195 2000-01-14
US18229600P 2000-02-14 2000-02-14
US60/182,296 2000-02-14
US54727600A 2000-04-11 2000-04-11
US19626700P 2000-04-11 2000-04-11
US19652700P 2000-04-11 2000-04-11
US19646000P 2000-04-11 2000-04-11
US19652800P 2000-04-11 2000-04-11
US60/162,498 2000-04-11
US60/196,267 2000-04-11
US60/196,527 2000-04-11
US60/160,860 2000-04-11
US60/134,118 2000-04-11
US60/547,276 2000-04-11
US60/196,460 2000-04-11
US60/134,117 2000-04-11
US60/134,114 2000-04-11
US60/196,528 2000-04-11

Publications (3)

Publication Number Publication Date
WO2000069897A2 WO2000069897A2 (en) 2000-11-23
WO2000069897A3 true WO2000069897A3 (en) 2001-11-08
WO2000069897A9 WO2000069897A9 (en) 2002-07-04

Family

ID=27584529

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2000/013161 WO2000069896A2 (en) 1999-05-14 2000-05-12 Molecular interactions in haematopoietic cells
PCT/US2000/013166 WO2000069897A2 (en) 1999-05-14 2000-05-12 Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013161 WO2000069896A2 (en) 1999-05-14 2000-05-12 Molecular interactions in haematopoietic cells

Country Status (4)

Country Link
EP (1) EP1178817A2 (en)
JP (2) JP2002543825A (en)
ES (1) ES2436624T3 (en)
WO (2) WO2000069896A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100890A2 (en) 1998-07-27 2001-05-23 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
US6942981B1 (en) 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US7595297B2 (en) 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
WO2002031512A2 (en) * 2000-10-13 2002-04-18 Arbor Vita Corporation Molecular interactions in hematopoietic cells
AU2002252015A1 (en) * 2001-02-16 2002-09-04 Arbor Vita Corporation Pdz domain interactions and lipid rafts
WO2002088175A1 (en) * 2001-04-24 2002-11-07 Otsuka Pharmaceutical Co., Ltd. Crohn's disease antibody-binding peptide and method of examining crohn's disease
AU2011211347B2 (en) * 2001-05-07 2015-02-19 Agriculture Victoria Services Pty Ltd Modification of plant and seed development and plant responses to stresses and stimuli (3)
DE10124342A1 (en) * 2001-05-18 2002-11-28 Biotecon Diagnostics Gmbh Amplification method for Yersinia pestis and Yersinia pseudotuberculosis, useful for their rapid detection and differentiation, also new primers and probes
EP1493028A4 (en) * 2001-07-06 2006-06-14 Genentech Inc Phage displayed pdz domain ligands
CA2457424A1 (en) * 2001-08-03 2003-02-20 Arbor Vita Corporation Molecular interactions in cells
AU2003291558B2 (en) * 2001-08-03 2009-08-13 Arbor Vita Corporation Molecular interactions in neurons
JP2003199459A (en) 2002-01-07 2003-07-15 Japan Science & Technology Corp Model nonhuman animal whose lymphocyte migration control function is lost
HUE038099T2 (en) 2004-12-21 2018-09-28 Musc Found For Res Dev Compositions and methods for promoting wound healing and tissue regeneration
AU2012202117B2 (en) * 2004-12-21 2014-06-26 Musc Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
CN101305091A (en) * 2005-02-24 2008-11-12 斯克里普斯研究学院 Isolated myeloid-like bone marrow cell populations and methods of treatment therewith
WO2007005948A2 (en) * 2005-07-01 2007-01-11 Arbor Vita Corporation Methods and compositions for diagnosis and treatment of viral and bacterial infections
EP1976869A2 (en) * 2005-12-23 2008-10-08 Partnership&Corp. Technology Transfer Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
JP5296530B2 (en) * 2006-04-07 2013-09-25 国立大学法人 筑波大学 Graft-versus-host disease prediction marker and use thereof
DK2819682T3 (en) 2012-03-01 2017-08-21 Firststring Res Inc TOPICAL GELLS CONTAINING ALPHA-CONNEXIN C-TERMINAL (ACT) PEPTIDES
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
WO2018204694A1 (en) * 2017-05-03 2018-11-08 Biomarin Pharmaceutical Inc. Improved lentiviruses for transduction of hematopoietic stem cells.
JP2022514354A (en) * 2018-12-20 2022-02-10 ザ・ユニバーシティ・オブ・シカゴ Methods and Compositions for Therapeutic Peptides for the Treatment of Cancer
CN114457005B (en) * 2022-01-12 2024-03-26 佛山市妇幼保健院 Separation and purification method of children urethra smooth muscle cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005347A1 (en) * 1996-07-22 1998-02-12 The Trustees Of Columbia University In The City Of New York Compounds that inhibit interaction between signal-transducing proteins and the glgf (pdz/dhr) domain and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005347A1 (en) * 1996-07-22 1998-02-12 The Trustees Of Columbia University In The City Of New York Compounds that inhibit interaction between signal-transducing proteins and the glgf (pdz/dhr) domain and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARCLAY A ET AL: "The leucocyte antigen factsbook", 1997, HARCOURT BRACES & COMPANY, US, SAN DIEGO, XP002154871, 227270 *
KOBAYASHI ICHIRO ET AL: "Identification of an autoimmune enteropathy-related 75-kilodalton antigen.", GASTROENTEROLOGY, vol. 117, no. 4, October 1999 (1999-10-01), pages 823 - 830, XP002154870, ISSN: 0016-5085 *
MAEKAWA KAZUHIKO ET AL: "Association of protein-tyrosine phosphatase PTP-BAS with the transcription-factor-inhibitory protein IkappaBalpha through interaction between the PDZ1 domain and ankyrin repeats.", BIOCHEMICAL JOURNAL, vol. 337, no. 2, 15 January 1999 (1999-01-15), pages 179 - 184, XP002154869, ISSN: 0264-6021 *

Also Published As

Publication number Publication date
WO2000069897A2 (en) 2000-11-23
WO2000069896A2 (en) 2000-11-23
JP2011102326A (en) 2011-05-26
JP2002543825A (en) 2002-12-24
WO2000069897A9 (en) 2002-07-04
WO2000069896A9 (en) 2002-10-03
WO2000069896A3 (en) 2001-07-05
EP1178817A2 (en) 2002-02-13
ES2436624T3 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
WO2000069897A3 (en) Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes
CA2285918A1 (en) Methods for concentrating ligands using magnetic particles
WO2001018244A3 (en) Selection system
DE69434942D1 (en) MULTIPURPOSE REAGENT SYSTEM FOR THE FAST LYSING OF FULL BLOOD SAMPLES
EP1062226A4 (en) High affinity nucleic acid ligands of complement system proteins
WO2002042422A3 (en) Molecular interactions in hematopoietic cells
AU5752696A (en) Dna binding antibodies
WO2003014303A3 (en) Molecular interactions in cells
MX9603532A (en) Nucleic acid delivery system, method of synthesis and uses thereof.
AU6042699A (en) Assays for measuring nucleic acid binding proteins and enzyme activities
DE68917736T2 (en) SYSTEM FOR MAGNETIC AFFINITY SEPARATION OF CELLS FROM CELL CONCENTRATES.
EP0199801A4 (en) Methods for protein binding enzyme complementation assays.
ZA986051B (en) Isolated mammalian membrane protein genes related reagents
WO1997038293A3 (en) Assays and reagents for identifying anti-fungal agents, and uses related thereto
AU5143099A (en) Protein fragment complementation assays for the detection of biological or drug interactions
CA2361987A1 (en) Goodpasture antigen binding protein
ATE285474T1 (en) HAEMOPHILUS ADHESION PROTEINS
AU1727597A (en) Purified sr-p70 protein
WO2002031512A3 (en) Molecular interactions in hematopoietic cells
AU649961B2 (en) Method for protein binding enzyme complementation assays
WO1999004266A3 (en) Interactions of atm, atr or dna-pk with p53
AU3063699A (en) Isolated mammalian membrane protein genes and related reagents
AU7193296A (en) Process for the ultrafiltration of biological matrices comprising peptides or proteins
WO2000069898A3 (en) Molecular interactions in allergy cells
AU2256197A (en) High affinity nucleic acid ligands of complement system proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US US US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US US US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US US US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-120, DESCRIPTION, REPLACED BY NEW PAGES 1-120; PAGES 121-123; CLAIMS, REPLACED BY NEW PAGES121-123; PAGES 1/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/14-14/14; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP